Alessa Therapeutics, Inc.
Polymer-based drug-loaded seed implants for sustained intraprostatic anti-androgen delivery in prostate cancer
- Sector
- Medtech
- Headquarters
- San Carlos, CA
- Founded
- 2018
- Latest Form D
- $25.4M, May 2025
- Total capital
- $32.4M
- Federal grants
- $799K
- 2 awards · 2021–2023
- Rank in peer group#53 of 445
- Private capital raised
- $31.6M
- 3 Form D · last May 2025
- 18 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 13 pending · first 2021
- Rank in peer group#44 of 445
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$25.4M
- Federal grantHealth and Human S · Phase I · Prostate Specific Anti-androgen Therapy for Localized Prostate Cancer$406K
- Federal grantHealth and Human S · Phase I · A novel implantable drug-eluting device that delivers an anti-androgen to the prostate to treat localized early stage prostate cancer$394K
- Private capital raisedForm D · SEC · 2nd filing$3.3M
- Private capital raisedForm D · SEC · 1st filing$3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 445 peers
Line = medianMedtech · Device
- Federal grants#53 · top 12%
- Granted patents#44 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Annie MitsakDirectorNamed in SEC Form D filings
- Cam GallagherExecutive Officer, DirectorNamed in SEC Form D filings
- Doug CrawfordDirectorNamed in SEC Form D filings
- Douglas CrawfordDirectorNamed in SEC Form D filings
- John MaroneyExecutive Officer, DirectorNamed in SEC Form D filings
- Pamela MunsterDirectorNamed in SEC Form D filings
Show all 10 people
- Peter ParkerDirectorNamed in SEC Form D filings
- Richard LimDirectorNamed in SEC Form D filings
- Steve TregayDirectorNamed in SEC Form D filings
- Zachary CollinsExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 18- GrantedImplantable Drug Delivery Devices For Localized Drug DeliveryUSPTOUS 12,576,063
- PendingDrug Implants Containing Darolutamide and Methods of Use ThereofUSPTOApplication 18223943
- PendingDrug Implants Containing Apalutamide and Methods of Use ThereofUSPTOApplication 18025611
Show all 18 patent records
- Implantable Drug Delivery Devices For Localized Drug DeliveryMar 17, 2026 · US 12,576,063Granted
- Drug Implants Containing Darolutamide and Methods of Use ThereofFeb 1, 2024 · Application 18223943Pending
- Drug Implants Containing Apalutamide and Methods of Use ThereofJan 18, 2024 · Application 18025611Pending
- Drug Implants Containing Enzalutamide And Methods Of Use ThereofAug 17, 2023 · Application 18138970Pending
- Drug Implants Containing Enzalutamide And Methods Of Use ThereofJun 6, 2023 · US 11,666,528Granted
- Implantable Drug Delivery Devices for Localized Drug DeliveryMay 31, 2022 · US 11,344,526Granted
- Implantable Drug Delivery Devices For Localized Drug DeliveryMay 24, 2022 · US 11,338,119Granted
- Implantable Drug Delivery Devices for Localized Drug DeliveryNov 16, 2021 · US 11,173,291Granted
- Implantable Drug Delivery Devices For Localized Drug DeliveryApplication PCTUS2020066215Pending
- Drug Implants Containing Apalutamide And Methods Of Use ThereofApplication 63084450Pending
- Drug Implants Containing Enzalutamide And Methods Of Use ThereofApplication PCTUS2022026178Pending
- Drug Implants Containing Olaparib And Methods Of Use ThereofApplication 63737384Pending
- Drug Implants Containing Niraparib And Methods Of Use ThereofApplication 63737392Pending
- Drug Implants Containing Talazoparib And Methods Of Use ThereofApplication 63612036Pending
- Drug Implants Containing Darolutamide and Methods of Use ThereofApplication 63368922Pending
- Drug Implants Containing Pamiparib And Methods Of Use ThereofApplication 63737373Pending
- Drug Implants Containing Apalutamide And Methods Of Use ThereofApplication PCTUS2021052230Pending
- Drug Implants Containing Enzalutamide And Methods Of Use ThereofApplication 63179915Pending
Related companies, and why
- UV Concepts Inc.Similar federal contract value in Medtech · null in contracts
- LAZARUS 3D, INC.Similar federal contract value in Medtech · null in contracts
- Curtis Mathes CorpSimilar federal contract value in Medtech · null in contracts
- ALUME BIOSCIENCES, INC.Similar federal contract value in Medtech · null in contracts
- BEACON BIOMEDICAL, INC.Similar federal contract value in Medtech · null in contracts
- DoseMatters Solutions LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .